Emerging trends in pharmaceutical design and drug manufacturing are shifting toward presenting the market with new ways to develop medications. Specialty medications continue to be a major area of pharmaceutical development and have become widely discussed in workers’ comp due to their significant costs. Although they represent approximately 1% of drug utilization, they account for nearly 7% of prescription drug costs and represent the fastest-growing segment of the U.S. pharmaceutical market. While specialty drug products are often associated with a hefty price tag, some can offer clinical advantages when deployed for the right patient at the right time, making careful oversight and patient selection imperative to achieving desired outcomes in this space. Watch the video blog to learn more.
More stories
Workers' Comp
News Release
CompAlliance
We are pleased to share that Coventry has completed the necessary steps to expand our Coventry Integrated Network® through the integration of CompA
Workers' Comp
CE Webinar
Look for a Broken Spirit, Not Just a Broken Bone: Evaluating Mental Health Needs in Workers' Comp
On-Demand
When someone gets hurt on the job, the workers’ compensation system is often adept at zeroing in on an injury and delivering timely care.
CE Webinar
Medical Marijuana Highs & Lows: Work Comp Clinical and Regulatory Trends
On-Demand
It seems like every day another state is in the news allowing for medical marijuana and cannabis programs.
Workers' Comp
CE Webinar
Legal Nurse Review & Medical Cost Projections Overview
On-Demand
This session on Legal Nurse Reviews and Medical Cost Projections provides a detailed overview of these specialty case management solutions and how
CE Webinar
High Impact Pharmaceuticals: A review of relatively low volume pharmacy cost-drivers
On-Demand
Pharmacy costs continue to represent a substantial portion of overall spending in healthcare.
CE Webinar
Networks 2.0: The Evolution of Provider Networks
On-Demand
Most people agree, the U.S. healthcare delivery system is broken. But it is not all bad news.